別品名 |
PD-L1 Antibody: Programmed cell death 1 ligand-1, programmed death ligand 1, PDL1, PDL-1, B7-H1
|
抗原部位 |
Extracellular domain
|
種由来 |
Human
|
標識物 |
Unlabeled
|
精製度 |
Ig fraction - Protein A
|
適用 |
Western Blot IHC paraffin embedding section Enzyme Linked Immunosorbent Assay Immuno Fluorescence Immunocytochemistry (cell)
|
免疫動物 |
Mouse
|
抗体クラス |
IgG1
|
クローン |
6H10
|
交差種 |
Human
|
GENE ID |
29126
|
Accession No.(Gene/Protein) |
NP_054862
|
Gene Symbol |
CD274
|
形状 |
液状
|
推奨品 |
ポジティブコントロール 品番:1340 - Human Stomach Carcinoma Tissue Lysate, ポジティブコントロール 品番:1315 - Human Tonsil Tissue
|
その他 |
[Protein GI Number]7661534 [Swiss-Prot No]Q9NZQ7
|
参考文献 |
Holling TM, Schooten E, and van Den Elsing PJ. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum. Immunol. 2004; 65:282-90. Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11:3887-95. LaGier J and Pober JS. Immune accessory functions of human endothelial cells are modulated by overexpression of B7-H1 (PDL1). Hum. Immunol. 2006; 67:568-78. Aydin AM, Woldu SL, Hutchinson RC, et al. Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.Onco. Targets Ther. 2017;10:1487-502.
|
※サムネイル画像をクリックすると拡大画像が表示されます。
Figure 1 Overexpression Validation of PD-L1 in 293 Cells Loading: 15 μg of lysates per lane.Antibodies: RF16035 (A, 0.25 μg/mL; B, 0.5 μg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-mouse IgG HRP conjugate at 1:5000 dilution.
Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile in Cell Lines Loading: 15 μg of lysates per lane.Antibodies: 4059 (2 μg/mL), RF16035 (2 μg/mL), and beta-actin (1 μg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit and or anti-mouse IgG HRP conjugate at 1:10000 and 1:5000 dilution, respectively.
Figure 3 Validation with PD-L1 siRNA Knockdown in HeLa Cells HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2) Loading: 10 μg of HeLa whole cell lysates per lane.Antibodies: RF16035 (2 μg/mL) and GAPDH (3783, 0.02 μg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-mouse IgG HRP conjugate at 1:5000 dilution.
Figure 4 Western Blot Validation of PD-L1 in Raji Cells Loading: Lysates/proteins at 15 μg per lane.Antibodies: RF16035 (4 μg/mL). 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-mouse IgG HRP conjugate at 1:10000 dilution.
Figure 5 Immunofluorescence Validation of PD-L1 in Transfected 293 Cells Immunofluorescent analysis of 4% paraformaldehyde-fixed PD-L1 transfected 293 cells labeling PD-L1 with RF16035 at 2 μg/mL, followed by goat anti-mouse IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue).
Figure 6 Immunofluorescence Validation of PD-L1 in Human Stomach Carcinoma Tissue Immunofluorescent analysis of 4% paraformaldehyde-fixed human stomach carcinoma tissue labeling PD-L1 with RF16035 at 2 μg/mL, followed by goat anti-mouse IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue).
Figure 7 Immunofluorescence Validation of PD-L1 in Human Tonsil Tissue Immunofluorescent analysis of 4% paraformaldehyde-fixed human tonsil tissue labeling PD-L1 with RF16035 at 2 μg/mL, followed by goat anti-mouse IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue).
Figure 8 Immunohistochemistry Validation of PD-L1 in Human Stomach Carcinoma Tissue Immunohistochemical analysis of paraffin-embedded human stomach carcinoma tissue using anti-PD-L1 antibody (RF16035) at 5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4℃. A goat anti-mouse IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Lower left: Use mouse IgG antibody at 1 μg/ml as control.
Figure 9 Immunohistochemistry Validation of PD-L1 in Human Tonsil Carcinoma Tissue Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-PD-L1 antibody (RF16035) at 5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4℃. A goat anti-mouse IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Lower left: Use mouse IgG antibody at 1 μg/ml as control.
Figure 10 Immunocytochemistry Validation of PD-L1 in PD-L1 Overexpressed 293 Cells Immunocytochemical analysis of PD-L1 transfected 293 cells using anti- PD-L1 antibody (RF16035) at 1 μg/mL. Cells was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4℃. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Lower left: Use mouse IgG antibody at 1 μg/mL as control.
|
|
Figure 1 Overexpression Validation of PD-L1 in 293 Cells Loading: 15 μg of lysates per lane.Antibodies: RF16035 (A, 0.25 μg/mL; B, 0.5 μg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-mouse IgG HRP conjugate at 1:5000 dilution.
|
|
|
メーカー |
品番 |
包装 |
PSC
|
RF16035
|
0.1 MG [1 mg/mL]
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
3週間程度
|
保存温度 |
-20℃
|
|